The same researchers working on 67Cu-SAR-bisPSMA are developing new radiopharmaceuticals, 67Cu-SAR-bisFAP and 67Cu-SAR-Bombesin, to treat prostate cancer patients with low or absent Prostate-Specific Membrane Antigen (PSMA) expression.
These patients often have limited effective treatment options. 67Cu-SAR-bisFAP targets the fibroblast activation protein (FAP) found in the tumor microenvironment and is expected to enter clinical trials by the end of 2025. It is a theranostic agent, allowing for both imaging and treatment.
67Cu-SAR-Bombesin targets the Gastrin-Releasing Peptide receptor (GRPr) and is already in Phase 1 clinical trials showing safety and potential efficacy. Both of these new treatments could also complement PSMA-targeting therapies in tumors that do express PSMA. These radiopharmaceuticals offer a significant advancement in prostate cancer care, particularly for patients who do not benefit from PSMA-directed treatments.
Let's hope!!
Welcoming New Era of Expanded Use of Radiotherapies
Lutetium - PSMA Earlier
